// STATE LEGISLATION TRACKER

Minnesota SF 4244: Miscellaneous technical corrections to laws and statutes

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Minnesota
Bill: SF 4244
Session: 2025-2026
Filed: 2026-03-09
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Minnesota SF4244 appears to be a broad technical-corrections bill, not a peptide, pharmacy, telehealth, or clinician-scope bill. Based on the title, subjects, and enacted status, it does not appear to change access to compounded peptides, off-label prescribing, 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No peptide-specific access change is apparent from the bill title or subjects
No apparent change to compounded peptide prescribing or dispensing
No apparent change to telehealth prescribing rules
No apparent NP or naturopathic scope expansion or restriction
Treat this as a housekeeping law unless specific amended text says otherwise

What to Watch For

Note Technical-corrections bills can touch many statutes, but the title does not signal peptide-policy changes.

Note If a clinic relies on a specific Minnesota pharmacy or licensing statute, check the exact amended section.

Note No FDA 503A/503B, controlled-substance, or PDMP change should be assumed from this bill alone.

Where the Bill Stands

The bill was enacted and has an effective date of August 1, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws